These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16498671)

  • 1. Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
    Tong FK; Chow S; Hedley D
    Cytometry B Clin Cytom; 2006 May; 70(3):107-14. PubMed ID: 16498671
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole blood fixation and permeabilization protocol with red blood cell lysis for flow cytometry of intracellular phosphorylated epitopes in leukocyte subpopulations.
    Chow S; Hedley D; Grom P; Magari R; Jacobberger JW; Shankey TV
    Cytometry A; 2005 Sep; 67(1):4-17. PubMed ID: 16080188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
    Adnane L; Trail PA; Taylor I; Wilhelm SM
    Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    Strumberg D; Richly H; Hilger RA; Schleucher N; Korfee S; Tewes M; Faghih M; Brendel E; Voliotis D; Haase CG; Schwartz B; Awada A; Voigtmann R; Scheulen ME; Seeber S
    J Clin Oncol; 2005 Feb; 23(5):965-72. PubMed ID: 15613696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single cell analysis of phosphoinositide 3-kinase/Akt and ERK activation in acute myeloid leukemia by flow cytometry.
    Bardet V; Tamburini J; Ifrah N; Dreyfus F; Mayeux P; Bouscary D; Lacombe C
    Haematologica; 2006 Jun; 91(6):757-64. PubMed ID: 16769577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
    Hedley DW; Chow S; Goolsby C; Shankey TV
    Toxicol Pathol; 2008 Jan; 36(1):133-9. PubMed ID: 18337231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
    Ulivi P; Arienti C; Amadori D; Fabbri F; Carloni S; Tesei A; Vannini I; Silvestrini R; Zoli W
    J Cell Physiol; 2009 Jul; 220(1):214-21. PubMed ID: 19288493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCC protein expression in hematopoietic cell populations and its relation to leukemogenesis.
    Inokuchi K; Miyake K; Takahashi H; Dan K; Nomura T
    J Clin Invest; 1996 Feb; 97(3):852-7. PubMed ID: 8609244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Study on the Characteristics of cell cycle and proliferation of CD34+ hematopoietic stem cells in myelodysplastic syndromes].
    Shi J; Shao ZH; Liu H; Jia HR; Sun J; Bai J; Wu YH; Jing LP; He GS; Cao YR; Wang XL; Tu MF; Hao YS; Yang TY
    Zhonghua Xue Ye Xue Za Zhi; 2004 Nov; 25(11):641-4. PubMed ID: 15634564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of molecular targets on the surface of CD34+CD38- bone marrow cells in myelodysplastic syndromes.
    Xie W; Wang X; Du W; Liu W; Qin X; Huang S
    Cytometry A; 2010 Sep; 77(9):840-8. PubMed ID: 20662087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunophenotype of myeloid cells in myelodysplastic syndromes and its clinical implications.
    Shao Z; Chen G; Lin Z; Zhang Y; Hao Y; Chu Y; Zheng Y; Qian L; Yang T; Yang C; Feng B
    Chin Med J (Engl); 1998 Jan; 111(1):28-31. PubMed ID: 10322648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
    Crump M; Hedley D; Kamel-Reid S; Leber B; Wells R; Brandwein J; Buckstein R; Kassis J; Minden M; Matthews J; Robinson S; Turner R; McIntosh L; Eisenhauer E; Seymour L
    Leuk Lymphoma; 2010 Feb; 51(2):252-60. PubMed ID: 20109071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flow cytometric chemosensitivity analysis of blasts from patients with acute myeloblastic leukemia and myelodysplastic syndromes: the use of 7AAD with antibodies to CD45 or CD34.
    Pallis M; Syan J; Russell NH
    Cytometry; 1999 Dec; 37(4):308-13. PubMed ID: 10547616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flow cytometric immunophenotypic characterization of pediatric and adult minimally differentiated acute myeloid leukemia (AML-M0).
    Kotylo PK; Seo IS; Smith FO; Heerema NA; Fineberg NS; Miller K; Greene ME; Chou P; Orazi A
    Am J Clin Pathol; 2000 Feb; 113(2):193-200. PubMed ID: 10664621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raf-1 kinase activation is uncoupled from downstream MEK/ERK pathway in cells treated with Src tyrosine kinase inhibitor PP2.
    Lee M
    Biochem Biophys Res Commun; 2006 Nov; 350(2):450-6. PubMed ID: 17010316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.